Vaxess Technologies Funding and Business Overview

Author

Reads 1.8K

Design of Brand Logo
Credit: pexels.com, Design of Brand Logo

Vaxess Technologies has secured significant funding to support the development of its innovative transdermal vaccine delivery technology. The company has received investments from notable venture capital firms.

The company's business model focuses on creating a more efficient and effective way to administer vaccines. This approach has the potential to revolutionize the way vaccines are delivered.

Vaxess Technologies is led by a team of experienced professionals with a deep understanding of the vaccine industry. Their expertise has been instrumental in shaping the company's vision and strategy.

The company's progress has been marked by several key milestones, including the completion of successful clinical trials.

You might like: Wildtype (company)

Funding and Valuation

Vaxess Technologies has secured a significant amount of funding, with a total of $118.99M raised over 24 rounds.

The company's latest funding round was a Debt - IV for $7.9M on September 8, 2025, with undisclosed investors participating.

Vaxess has also received funding from notable investors such as RA Capital Management and Engine Ventures.

Here's a breakdown of the company's recent funding rounds:

The company plans to use the funds to continue its work in GLP-1 therapeutics and expand its manufacturing capabilities.

Funding, Valuation & Revenue

Credit: youtube.com, Worth Billions But No Profits: Startup Valuation Explained

Vaxess Technologies has secured a total of $118.99M in funding across 24 rounds. Their latest funding round was a Debt - IV for $7.9M on September 8, 2025.

This funding round was led by undisclosed investors, who provided the necessary capital to support the company's growth. The valuation of the company after this round is not publicly disclosed.

Vaxess Technologies has received funding from various investors, including Engine Ventures and RA Capital Management. In their Series C - II round, they secured $9M in funding on April 9, 2025.

However, the valuation of the company after this round is also not publicly disclosed. It's worth noting that the company's revenue figures are not available for the past fiscal year.

Here's a summary of Vaxess Technologies' funding rounds:

Overall, Vaxess Technologies has been able to secure significant funding to support its growth and development.

$12M for Shelf-Stable MIMIX Skin Patch

Vaxess Technologies recently received $12 million in additional funding to develop its shelf-stable MIMIX skin patch for vaccines and therapeutics. This brings the company's total equity and non-dilutive funding to more than $90 million.

Female Scientist in White Lab Coat Using a Microscope
Credit: pexels.com, Female Scientist in White Lab Coat Using a Microscope

The funding round included investors RA Capital Management, Engine Ventures, GHIC, and Mission Bio Capital. Rachel Sha, the new CEO of Vaxess, has over 20 years of experience in life sciences, including large biopharma companies like Novartis, Genzyme, and Sanofi.

Vaxess plans to use the funds to advance its GLP-1 work, continue in vivo work with mRNA, and expand and scale manufacturing process capabilities. The company has recently demonstrated the feasibility of GLP-1 delivery and partnered with leading biopharma companies in vaccines.

The MIMIX patch is a skin patch that can deliver therapeutics over time, mimicking how natural infections interact with the body. It features a soluble microarray with tips that gradually dissolve into the body after removal.

Rachel Sha expressed her enthusiasm for leading the Vaxess team, citing the company's progress in demonstrating the commercial viability of its industry-leading skin patch for drug delivery.

Broaden your view: Array BioPharma

Investors

Vaxess Technologies has a total of 19 investors. Their funding rounds are structured in a way that makes it easy to track their investments.

Credit: youtube.com, Vaxess Technologies Company Introduction

RA Capital Management is one of the key investors, having invested in Vaxess Technologies's Series C - II funding round. They have a strong presence in the company, with a 5-round investment history including Series B, Series B - II, Series B - III, Series C, and Series C - II.

Engine Ventures is another notable investor, having invested in 2 rounds, Series C and Series C - II (2025). They are a venture capital firm based in Massachusetts.

The National Institute of Diabetes and Digestive and Kidney Diseases is a government investor, having invested in 3 grants: Grant - II, Grant - V (2021), and Grant - VI (2024). They are based in Maryland.

The following table shows the details of Vaxess Technologies's investors:

Mission BioCapital and Global Health Investment Corporation are also investors, but their details are not publicly available.

Eric Hintz

Lead Assigning Editor

Eric Hintz is a seasoned Assigning Editor with a keen eye for detail and a passion for storytelling. With a background in journalism, Eric has honed his skills in selecting and assigning compelling articles that captivate readers. As a seasoned editor, Eric has a proven track record of identifying emerging trends and topics, including the inner workings of major financial institutions, such as "Banking Headquarters".

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.